ZVRA

Zevra Therapeutics Inc. a rare disease company melding science discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder stimulant use disorder and CNS rare diseases including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy is based on its prodrug of d-methylphenidate known as serdexmethylphenidate. It is also developing KP879 a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition the company has received FDA approval for AZSTARYS a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older and for APADAZ an immediate-release combination product containing benzhydrocodone a prodrug of hydrocodone and acetaminophen. The company's product pipeline include arimoclomol It has collaboration and license agreement with KVK-Tech Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm Inc. and changed its name to Zevra Therapeutics Inc. in February 2023. Zevra Therapeutics Inc. was incorporated in 2006 and is headquartered in Celebration Florida.